期刊
NATURE REVIEWS DRUG DISCOVERY
卷 12, 期 11, 页码 847-865出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd4140
关键词
-
资金
- University of Texas MD Anderson Research Trust
- University of Texas System Regents Research Scholar
- CLL Global Research Foundation
- US National Institutes of Health (NIH)/US National Cancer Institute (NCI) [CA135444]
- US Department of Defense Breast Cancer Idea Award
- Developmental Research Awards in breast cancer, ovarian cancer, brain cancer, prostate cancer, multiple myeloma and leukaemia [P50 CA100632]
- Specialized Programs of Research Excellence (SPOREs) [P50 CA097007]
- Sister Institution Network Fund (SINF) grant from the MD Anderson Cancer Center
- German Cancer Research Center (DKFZ) in chronic lymphocytic leukaemia
- SINF grant in colorectal cancer
- Laura and John Arnold Foundation
- RGK Foundation
- Jean Perkins Foundation
- Nautica Malibu Triathlon Funds
- Pablove Foundation
- St. Baldrick's Foundation
- Southern California Clinical and Translational Science Institute
- Funds from the Saban Research Institute
- NCI [P30CA014089]
- Hugh and Audy Lou Colvin Foundation
- T.J. Martell Foundation
The first cancer-targeted microRNA (miRNA) drug - MRX34, a liposome-based miR-34 mimic - entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in April 2013, and miRNA therapeutics are attracting special attention from both academia and biotechnology companies. Although miRNAs are the most studied non-coding RNAs (ncRNAs) to date, the importance of long non-coding RNAs (lncRNAs) is increasingly being recognized. Here, we summarize the roles of miRNAs and lncRNAs in cancer, with a focus on the recently identified novel mechanisms of action, and discuss the current strategies in designing ncRNA-targeting therapeutics, as well as the associated challenges.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
